Pfizer Inc. did not provide any more details about those cases and cautioned the initial protection rate might change by the time the study ends. Even revealing such early data is highly unusual.
“We’re in a position potentially to be able to offer some hope,” Dr. Bill Gruber, Pfizer’s senior vice president of clinical development, told The Associated Press. “We’re very encouraged.”
Emory University infectious disease expert Dr. Carlos del Rio called the results “exciting” in a telephone interview with The Atlanta Journal-Constitution on Monday.
Del Rio said he wanted to see the data but is encouraged that it was more than 90% effective and that 42% of the study participants are from diverse backgrounds, which experts hope will increase the public’s confidence in taking a vaccine when it is approved.
Emory is working with Moderna, a Massachusetts-based company, on a vaccine.
Del Rio, who believes a vaccine will be ready by the end of the year, compared the rapid speed of its development to President John F. Kennedy’s call for a moon landing by the end of the 1960s, which was successful in 1969.
“This is just unbelievable,” del Rio said.
Dr. Ted Ross, director of the University of Georgia’s Center for Vaccines and Immunology and Georgia Research Alliance eminent scholar, called this early look at the data on the coronavirus vaccine a “highly significant finding."
”This is an encouraging first step and good news. Let’s hope that other vaccine candidates work just as well to give us lots of different vaccine options," said Ross in an email.
And Professor Baozhong Wang at Georgia State’s Institute for Biomedical Sciences also described the promising preliminary results as “terrific news.”
Wang went on to say, “People should know that a promising COVID-19 vaccine is very close” which could ultimately put us on a path of ending the pandemic.
Even so, Ross and Wang stressed more data is needed and several questions remain about the vaccine including how long immunity would last.
Ross said he would also like to see the breakdown of protective immune responses by gender and by race to make sure each of these populations have similar immune responses and similar levels of protection against infection.
Another question will be whether the vaccine can offer protection to unvaccinated people. It’s one thing for a vaccine to protect the infected person from developing COVID-19. But there are questions about whether the vaccinated person, even if they don’t develop COVID-19, could still be infected with the coronavirus and shed (and spread) the virus.
Authorities have stressed it’s unlikely any vaccine will arrive much before the end of the year, and limited initial supplies will be rationed.
“We need to see the data, but this is extremely promising,” said Dr. Jesse Goodman of Georgetown University.
He ticked off many questions still to be answered including how long the vaccine’s effects last and if it also protects older people as well as younger people.
If Pfizer’s vaccine ultimately pans out, “it’s going to be a while before this has a major impact at the population level,” said Goodman, a former chief of the Food and Drug Administration’s vaccine division.
The interim results were “an interesting first signal,” but questions remain, said Marylyn Addo, head of the tropical medicine unit at UKE hospital in Hamburg, Germany.
Global markets, already buoyed by the victory of U.S. President-elect Joe Biden, exploded on the news from Pfizer. All major markets in Europe, where infections have soared, are up 5%. In the U.S., Dow futures also rose 5% and were up about 1,400 points just over two hours before the opening bell.
The shots made by Pfizer and its German partner BioNTech are among 10 possible vaccine candidates in late-stage testing around the world — four of them so far in huge studies in the U.S. Another U.S. company, Moderna Inc., also has said it hopes to be able to file an application with the FDA later this month.
Volunteers in the final-stage studies — and the researchers — don’t know who received the real vaccine or a dummy shot. But a week after their second required dose, Pfizer’s study began counting the number who developed COVID-19 symptoms and were confirmed to have the coronavirus.
Because the study hasn’t ended, Gruber couldn’t say how many in each group had infections. Doing the math, that would mean almost all the infections counted so far had to have occurred in people who got the dummy shots.
Pfizer doesn’t plan to stop its study until it records 164 infections among all the volunteers, a number that the FDA has agreed is enough to tell how well the vaccine is working. The agency has made clear that any vaccine must be at least 50% effective.
No participant so far has become severely ill, Gruber said. Nor could he provide a breakdown of how many of the infections had occurred in older people, who are at highest risk from COVID-19.
Participants were tested only if they developed symptoms, leaving unanswered whether vaccinated people could get infected but show no symptoms and unknowingly spread the virus.
The FDA has required that U.S. vaccine candidates be studied in at least 30,000 people. In addition to adequate numbers of older adults, those studies must also include other groups at high risk, including minorities and people with chronic health problems.
And it told companies they must track half their participants for side effects for at least two months, the time period when problems typically crop up. Pfizer expects to reach that milestone later this month, but said Monday no serious safety concerns have been reported.
Because the pandemic is still raging, manufacturers hope to seek permission from governments around the world for emergency use of their vaccines while additional testing continues — allowing them to get to market faster than normal but raising concerns about how much scientists will know about the shots.
The FDA’s scientific advisers last month said they worry that allowing emergency use of a COVID-19 vaccine could damage confidence in the shots and make it harder to ever find out how well they really work. Those advisers said it’s critical these massive studies are allowed to run to completion.
Helena Oliviero and Eric Stirgus of The Atlanta Journal-Constitution contributed to this report.